For healthy adults aged 70 and older, taking aspirin daily does not prevent heart attacks, strokes, or cancer deaths, but it does increase the chance of dangerous bleeding, making the risks greater than the benefits.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of all randomized controlled trials comparing low-dose aspirin to placebo in adults ≥70 years for primary prevention, with pooled estimates of cardiovascular events, major bleeding, cancer incidence, and all-cause mortality.
A systematic review and meta-analysis of all published and unpublished randomized controlled trials enrolling adults aged 70 years or older without prior cardiovascular disease, randomized to daily low-dose aspirin (75–100 mg) versus placebo for at least 5 years, with pre-specified primary outcomes of major cardiovascular events (non-fatal MI, stroke, CV death), major bleeding (intracranial, GI, other), cancer incidence, cancer mortality, and all-cause mortality, analyzed by intention-to-treat with subgroup analysis by age, sex, and comorbidity burden.
A single high-quality RCT can establish whether low-dose aspirin causally increases bleeding risk or fails to reduce cardiovascular events or cancer mortality in healthy elderly adults.
A double-blind, placebo-controlled RCT of 10,000 healthy adults aged 70–80 years without prior CVD or cancer, randomized to daily 81 mg aspirin or placebo for 7 years, with primary endpoints of first major cardiovascular event, first major bleeding event, and cancer mortality, monitored via centralized adjudication, with secondary outcomes including disability-free survival, GI symptoms, and NSAID use.
A prospective cohort study can estimate the real-world association between aspirin use and bleeding or cardiovascular outcomes in elderly populations over time, adjusting for confounders like NSAID use and frailty.
A prospective cohort study following 20,000 community-dwelling adults aged 70+ years without CVD, stratified by aspirin use (yes/no, dose, duration), with annual assessments of cardiovascular events, bleeding episodes, cancer diagnoses, and medication use, adjusting for comorbidities, renal function, fall risk, and NSAID co-use.
A case-control study can assess whether prior aspirin use is more common among elderly individuals who experienced major bleeding compared to matched controls without bleeding.
A matched case-control study comparing 1,000 elderly patients (≥70) hospitalized for major GI or intracranial bleeding to 2,000 age- and sex-matched controls without bleeding, assessing prior aspirin use (dose, duration, formulation) and concomitant NSAID use via medical records and pharmacy data.
A cross-sectional survey can estimate the prevalence of aspirin use among elderly populations and its correlation with current bleeding symptoms or cardiovascular risk factors.
A nationally representative cross-sectional survey of 5,000 adults aged 70+ in the U.S. assessing current aspirin use, recent bleeding episodes (past 12 months), and cardiovascular risk factors via structured interviews and medical record abstraction.